BRIEF published on 07/01/2026 at 09:27, 14 days 15 hours ago Valerio Therapeutics is preparing to acquire Etherna Immunotherapies Valerio Therapeutics Biotechnology Investment Etherna Acquisition RNA Drugs Mergers Of Companies
BRIEF published on 07/01/2026 at 09:27, 14 days 15 hours ago Valerio Therapeutics Proposes to Acquire Etherna Immunotherapies Biotechnology Valerio Therapeutics Acquisition Deal RNA Medicines Etherna Immunotherapies
PRESS RELEASE published on 07/01/2026 at 09:22, 14 days 15 hours ago Inside Information / Other news releases Valerio Therapeutics announces binding offer to acquire Etherna Immunotherapies, creating global leader in targeted RNA medicines. Strategic move unlocked by leading investors Acquisition Valerio Therapeutics RNA Medicines Targeted Delivery Etherna Immunotherapies
BRIEF published on 06/16/2026 at 19:48, 29 days 4 hours ago Valerio Therapeutics Appoints New CEO and Confirms AGM Resolutions Biotechnology CEO Transition Valerio Therapeutics Gilles Besin RNA Medicines
PRESS RELEASE published on 06/16/2026 at 19:43, 29 days 4 hours ago Inside Information / Other news releases Valerio Therapeutics appoints Gilles Besin as CEO, approved all resolutions at annual general meeting. Besin brings deep RNA and targeted delivery expertise to drive innovation Annual General Meeting Valerio Therapeutics Gilles Besin RNA Medicines Targeted Delivery
BRIEF published on 12/17/2025 at 11:02, 6 months 29 days ago Valerio Therapeutics Welcomes Professor Eric Vivier to its Board of Directors Board Of Directors Oncology Immunology Valerio Therapeutics Eric Vivier
BRIEF published on 12/17/2025 at 11:02, 6 months 29 days ago Valerio Therapeutics Appoints Professor Eric Vivier as Board Observer Board Of Directors Immunology Valerio Therapeutics Professor Eric Vivier Oncology Strategy
PRESS RELEASE published on 12/17/2025 at 10:57, 6 months 29 days ago Inside Information / Other news releases Valerio Therapeutics appoints Prof. Eric Vivier as Observer to Board of Directors. Prof. Vivier, a renowned immunologist, will bring over 30 years of experience to drive innovative tumor treatment approaches Board Of Directors Valerio Therapeutics Professor Eric Vivier Immunologist Tumor Treatment
BRIEF published on 10/30/2025 at 09:03, 8 months 16 days ago Valerio Therapeutics' financial and strategic review for the first half of 2025 Strategic Refocusing Valerio Therapeutics 2025 Financial Results V-Body Platforms Seeking Partnerships
Published on 07/15/2026 at 23:00, 1 hour 33 minutes ago Battery X Metals Completes First-Generation Proprietary Battery Adaptor for Tesla Model 3 and Model Y, Marking a Significant Commercial Readiness Milestone for its Patent-Pending Lithium-Ion Battery Rebalancing Platform
Published on 07/15/2026 at 22:45, 1 hour 48 minutes ago Mako Mining Announces Q2 2026 Production Results with Record Gold Sold of 14,610 Au oz., Revenues of ~US$63 Million and Cash and Securities Balance of US$112 Million
Published on 07/15/2026 at 22:15, 2 hours 18 minutes ago Loar Holdings Inc. Announces Date and Time for Second Quarter 2026 Earnings and Conference Call
Published on 07/15/2026 at 14:30, 10 hours 3 minutes ago Avant Brands Reports Q2 2026 Results Highlighted by 34% Growth in Recreational Revenue
Published on 07/15/2026 at 14:30, 10 hours 3 minutes ago Innodata to Report Second Quarter 2026 Results
Published on 07/15/2026 at 20:14, 4 hours 19 minutes ago EQS-Adhoc: Bajaj Mobility AG: Preliminary figures for Q2 / 2026
Published on 07/15/2026 at 19:42, 4 hours 51 minutes ago EQS-Adhoc: Cherry SE: Adjusted EBITDA for the first half of 2026 significantly above prior-year operating result
Published on 07/15/2026 at 18:28, 6 hours 4 minutes ago Vulcan receives initial strategic funding for Lionheart Project
Published on 07/15/2026 at 18:15, 6 hours 18 minutes ago Northern Data AG – Invitation to Annual General Meeting on 25 August 2026
Published on 07/15/2026 at 17:45, 6 hours 48 minutes ago Disclosure of Share Capital and Voting Rights Outstanding as of June 30, 2026
Published on 07/15/2026 at 17:45, 6 hours 48 minutes ago Half yearly report on the liquidity contract
Published on 07/15/2026 at 17:40, 6 hours 53 minutes ago Report on share repurchases from 8 to 14 July 2026
Published on 07/13/2026 at 18:00, 2 days 6 hours ago PR Icade - Icade regains full ownership of the Eqho Tower in La Défense
